SGLT2 inhibitors Archives -

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication

Bayer data for kidney disease hope finerenone sets up filings

https://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/

News/ News/ R&D/ Top stories

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance, SGLT2 inhibitors 0 Comment

The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but

Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failure

https://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/

Janssen J&J Johnson and Johnson pharmaceutical companies

Digital/ News/ News

Janssen taps wearable tech in Invokana heart failure trial

Phil Taylor digital, heart failure, Invokana, Janssen, Johnson & Johnson, SGLT2 inhibitors, wearable 0 Comment

Janssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world

Janssen taps wearable tech in Invokana heart failure trial

https://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/

Market Access/ News/ News/ News/ R&D/ Top stories

Boehringer, Lilly start acute heart failure trial with Jardiance

Phil Taylor Boehringer Ingelheim, Eli Lilly, heart failure, Jardiance, SGLT2 inhibitors 0 Comment

Boehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure,

Boehringer, Lilly start acute heart failure trial with Jardiance

https://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/

Market Access/ News/ News

AZ’s Forxiga gets heart claim data on its EU label

Phil Taylor AstraZeneca, cardiovascular outcomes, Forxiga, SGLT2 inhibitors, Type 2 diabetes 0 Comment

AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2

AZ’s Forxiga gets heart claim data on its EU label

https://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/

News/ News/ Top stories

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure

Phil Taylor Boehringer Ingelheim, cardiovascular outcomes, Eli Lilly, heart failure, SGLT2 inhibitors 0 Comment

Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease

FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure

https://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/

Diabetes/ Diabetes/ News/ News/ Patients

FDA warns of genital gangrene risk with diabetes drug class

Piotr Wnuk Diabetes, FDA warning, SGLT2 inhibitors 0 Comment

The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including

FDA warns of genital gangrene risk with diabetes drug class

https://pharmaphorum.com/news/risk-sglt2-inhibitors-fda-warns/

R&D/ Views & Analysis/ Views and analysis

SGLT2 inhibitors: an emerging option for cardiologists?

Daniel Ghinn cardiology, SGLT2 inhibitors 0 Comment

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists

SGLT2 inhibitors: an emerging option for cardiologists?

https://pharmaphorum.com/views-and-analysis/sglt2-inhibitors-cardiologists-option/

News/ UK & Europe

AZ’s diabetes combination Qtern approved in Europe

Andrew McConaghie AstraZeneca, Diabetes, SGLT2 inhibitors 0 Comment

The European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2

AZ’s diabetes combination Qtern approved in Europe

https://pharmaphorum.com/transversal-categories/uk-and-europe/azs-diabetes-combination-qtern-approved-europe/

Trending

SGLT2 inhibitors

Login